How should encorafenib‑related interstitial lung disease be monitored and managed?

Encorafenib-Related Interstitial Lung Disease: Monitoring and Management

Direct Recommendation

Immediately discontinue encorafenib at any grade of suspected ILD, initiate corticosteroids for grade ≥2 pneumonitis, and permanently discontinue for grade 3-4 events. Early detection and drug cessation are critical, as delayed diagnosis leads to irreversible fibrotic lung damage and higher mortality 1.

Monitoring Strategy

Baseline Assessment

• Obtain baseline chest CT scan before initiating encorafenib
• Document baseline oxygen saturation and pulmonary function
• Identify high-risk patients: those with preexisting ILD (OR 4.8-25.3 for developing drug-related pneumonitis), age <65 years, oxygen saturation <95%, moderate/severe renal impairment, or lung comorbidities 1, 2

Surveillance Timeline

Most drug-related ILD occurs within the first 12 months of treatment, with median onset around 5-6 months for molecular targeted agents 3, 2. However, 87% of events occur within 12 months of first dose 2.

• Months 1-6: Monitor most intensively with clinical assessment every 2-4 weeks

  • Assess for new respiratory symptoms (dyspnea, cough, fever)
  • Check oxygen saturation at each visit
  • Consider chest CT at 3 months for high-risk patients

• Months 6-12: Continue vigilant monitoring every 4-8 weeks

  • Clinical assessment for respiratory symptoms
  • Oxygen saturation monitoring

• Beyond 12 months: Maintain routine surveillance every 3 months, as late-onset ILD can occur

Key Clinical Pitfall

Radiologic evidence of ILD often precedes clinical recognition by a median of 43 days 2. This means chest CT imaging may detect ILD before symptoms develop, emphasizing the importance of scheduled imaging surveillance rather than waiting for symptoms.

Management Algorithm

Grade 1 (Asymptomatic, radiographic findings only)

• Hold encorafenib immediately
• Obtain chest CT with multidisciplinary review (pulmonology, radiology, oncology) 1
• Monitor closely with repeat imaging in 1-2 weeks
• Consider reintroduction only after complete radiographic resolution
• Corticosteroids generally not required

Grade 2 (Symptomatic, not interfering with ADLs)

• Discontinue encorafenib
• Initiate corticosteroids: prednisone 0.5-1 mg/kg/day (or equivalent) 1
• Hospitalization may be required for monitoring
• Supplemental oxygen as needed
• Multidisciplinary evaluation mandatory
• Taper corticosteroids over 4-6 weeks after improvement
• Do not rechallenge with encorafenib

Grade 3-4 (Severe symptoms, interfering with ADLs or life-threatening)

• Permanently discontinue encorafenib 1
• Immediate hospitalization required
• High-dose corticosteroids: methylprednisolone 1-2 mg/kg/day IV or prednisone 1-2 mg/kg/day PO 1
• Supplemental oxygen, consider noninvasive or invasive mechanical ventilation as needed
• If no improvement within 48 hours on corticosteroids, escalate to:
  • Infliximab, OR
  • Mycophenolate mofetil, OR
  • IV immunoglobulin 1
• Extended corticosteroid taper over 6-12 weeks after stabilization

Special Considerations

Preexisting ILD

Patients with preexisting ILD face substantially higher risk (OR 4.8-25.3) and worse outcomes (OR 2.27 for fatal outcomes) 1. Consider alternative therapies in patients with significant preexisting ILD, as the risk-benefit ratio may be unfavorable. If encorafenib is essential, implement intensive monitoring with baseline and monthly chest CT for the first 6 months.

Pharmacovigilance

Report all cases of encorafenib-related ILD to pharmacovigilance programs (FDA MedWatch, WHO VigiAccess) to enhance safety surveillance 1.

Evidence Quality Note

While the Fleischner Society guidelines 1 provide robust recommendations for drug-related pneumonitis management from molecular targeted agents, specific data on encorafenib-related ILD is limited. The management approach extrapolates from general principles for BRAF inhibitors and other molecular targeted therapies, which share similar mechanisms and ILD patterns. The median time-to-onset data from other targeted agents 3 suggests vigilance is most critical in the first 3-6 months, though encorafenib-specific timing may vary.